Efficacy and safety of Miacalcic ( salmon calcitonin ) in osteoporotic fracture patients: A 12 weeks,open-label,multicenter,observational study
XUE Qing-yun,JI Quan,ZHANG Liang,WEN Liang-yuan,SHENG Zheng-yan,LI Yi-zhong,ZHENG Ming,LIN Yu-fen,JIANG Wen-xue,JIA Shi-kong,BAI Xue-song,WANG Bing-qiang,XIAO KE-ming,LU Qing-lin,RUI Gang,PAN Wei-ming,YANG Lian-zi,MA Xiong-jun,HE Rong-xin,MA Chu-ping,OU-yang Yue-ping,XU Fu-xiang,ZHANG Jian-zhong,ZHANG Chun
DOI: https://doi.org/10.3969/j.issn.1674-2591.2013.02.008
2013-01-01
Abstract:Objective To assess the efficacy,safety and compliance of Miacalcic in osteoporotic fracture patients. Methods An open-label,multicenter,non-interventional,post marketing surveillance. Patients with osteoporotic intertrochanteric fracture were treated with internal fixation. All the patients were treated with Miacalcic injection or nasal spray and were followed up for 12 weeks. The extent of pain relief,fracture healing rate and the safety data were recorded in the observational period. Results Three hundred and twenty seven cases ( 92 males,235 females) from 22 centers were enrolled in the study and 317 cases were followed up for 12 weeks. The age ranged between 53 and 89 years old. The average VAS score at the baseline,1st week,and 4th week were 83. 6,55. 6,and 19. 1. The SF-36 score at the baseline,2nd week,4th week,and 12th week were 79. 3,92. 0,106. 9,and 126. 8,respectively. At the end of 12th week the fracture healing rate is 89. 9% . Conclusion Miacalcic could effectively relieve the pain after acute fracture and improve the life quality without negative effect to the fracture healing.